Lung cancer at ASCO 2023: ADAURA and ADCs

7 Views

07/14/23

Martin Wermke, MD, University Hospital Carl Gustav Carus, Dresden, Germany, presents his highlights in lung cancer at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress, including updates in antibody-drug conjugates (ADCs) and findings from the Phase III ADAURA trial (NCT02511106) of osimertinib in lung cancer. The trial provides novel strategies in the management of EGFR-mutant non-small cell lung cancer. This interview took place at the ASCO 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.